Vincent Vuaroqueaux
YOU?
Author Swipe
View article: Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
BI-847325 is an ATP-competitive inhibitor of MEK/Aurora kinases with the potential to treat a wide range of cancers. In a panel of 294 human tumor cell lines in vitro, BI-847325 was found to be a highly selective inhibitor that was …
View article: FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in 11 solid tumor models grown as subcutaneous xenografts in nude mice. A, Tumor growth curves over time are shown as the relative tumor volumes (%). BI-847325 (either at 80 or 4…
View article: Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S2 shows the relative body weights of the mice treated with BI-847325 as monotherapy (first in vivo experiment).
View article: TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Human cell line panel (n = 294) and cancer types investigated for BI-847325 efficacy
View article: Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S2 shows the relative body weights of the mice treated with BI-847325 as monotherapy (first in vivo experiment).
View article: FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Association between cell line sensitivities to BI-847325 in vitro and their oncogenic alterations in the RAS/RAF/MAPK pathway. Top: Waterfall plot of BI-847325 Abs IC70 values (y-axis) per cell line (x-axis)…
View article: FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in combination with capecitabine. Combinations (simultaneously or sequentially) were compared with both monotherapies. A, Tumor growth curves are represented as the relative tumo…
View article: FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 4 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in 11 solid tumor models grown as subcutaneous xenografts in nude mice. A, Tumor growth curves over time are shown as the relative tumor volumes (%). BI-847325 (either at 80 or 4…
View article: TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
TABLE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Human cell line panel (n = 294) and cancer types investigated for BI-847325 efficacy
View article: FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Association between cell line sensitivities to BI-847325 in vitro and their oncogenic alterations in the RAS/RAF/MAPK pathway. Top: Waterfall plot of BI-847325 Abs IC70 values (y-axis) per cell line (x-axis)…
View article: FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vitro antiproliferative activity of BI-847325 tested in 294 cancer CLs. A, BI-847325 Chemical structure. B, individual dose–response curves of BI-847325 in 294 solid tumor and hematologic cancer CLs after 4 days of …
View article: Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S3 shows the relative body weights of the mice treated with BI-847325 or capecitabine as monotherapy and in combination (second in vivo experiment).
View article: FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Comparison between the in vitro antiproliferative activities of BI-847325 and the MEK inhibitor GDC-0623. A, Contingency table with counts of CLs per class of sensitivity to BI-847325 and GDC-0623 (cutoff for Abs IC70
View article: Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S3 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S3 shows the relative body weights of the mice treated with BI-847325 or capecitabine as monotherapy and in combination (second in vivo experiment).
View article: Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Five supplementary tables 1 to 5 giving more information about:- the culture conditions and molecular profile of the 294 cell lines tested.- the IC70 range per cancer type.- the number of "sensitive" and "less sensitive to resistant" cell …
View article: Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Tables 1-5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Five supplementary tables 1 to 5 giving more information about:- the culture conditions and molecular profile of the 294 cell lines tested.- the IC70 range per cancer type.- the number of "sensitive" and "less sensitive to resistant" cell …
View article: Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S1 shows a scatter plot of the GDC-0623 IC70 values across cell lines sorted by cancer entities.
View article: Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Supplementary Figure S1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Supplementary Figure S1 shows a scatter plot of the GDC-0623 IC70 values across cell lines sorted by cancer entities.
View article: Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
Data from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
BI-847325 is an ATP-competitive inhibitor of MEK/Aurora kinases with the potential to treat a wide range of cancers. In a panel of 294 human tumor cell lines in vitro, BI-847325 was found to be a highly selective inhibitor that was …
View article: FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 1 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vitro antiproliferative activity of BI-847325 tested in 294 cancer CLs. A, BI-847325 Chemical structure. B, individual dose–response curves of BI-847325 in 294 solid tumor and hematologic cancer CLs after 4 days of …
View article: FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 2 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
Comparison between the in vitro antiproliferative activities of BI-847325 and the MEK inhibitor GDC-0623. A, Contingency table with counts of CLs per class of sensitivity to BI-847325 and GDC-0623 (cutoff for Abs IC70
View article: FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
FIGURE 5 from High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
In vivo antitumor growth efficacy of BI-847325 in combination with capecitabine. Combinations (simultaneously or sequentially) were compared with both monotherapies. A, Tumor growth curves are represented as the relative tumo…
View article: High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models
High <i>In Vitro</i> and <i>In Vivo</i> Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models Open
BI-847325 is an ATP-competitive inhibitor of MEK/Aurora kinases with the potential to treat a wide range of cancers. In a panel of 294 human tumor cell lines in vitro, BI-847325 was found to be a highly selective inhibitor that was active …
View article: Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy Open
Purpose: We have shown that DNA methylation of the PITX2 gene predicts risk of distant recurrence in steroid hormone receptor-positive, node-negative breast cancer. Here, we present results from a multicenter study investigating whe…
View article: Data from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Data from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors Open
Purpose: Targeting MET in cancer is hampered by lack of diagnostics that accurately reflect high MET signaling and dependence. We hypothesized that assays reflecting MET signaling associated protein complexes could redefine tumors d…
View article: Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy Open
Purpose: We have shown that DNA methylation of the PITX2 gene predicts risk of distant recurrence in steroid hormone receptor-positive, node-negative breast cancer. Here, we present results from a multicenter study investigating whe…
View article: Supplementary Figures 1-5, Supplementary Tables 1-3, Supplementary References from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Supplementary Figures 1-5, Supplementary Tables 1-3, Supplementary References from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors Open
Figure S1: Adaptor knockdowns. A) 72hr titration of BKM120 in MET-amplified NSCLC cell lines analyzed by Cell Titer Glo 72 hr. Figure S2: Distribution of tumor types for PDX models used in MET:GRB2 PLA survey. Figure S3: Immunohistochemist…
View article: Supplementary Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
Supplementary Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy Open
Supplementary Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
View article: Supplementary Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
Supplementary Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy Open
Supplementary Data from DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy
View article: Data from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors
Data from MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors Open
Purpose: Targeting MET in cancer is hampered by lack of diagnostics that accurately reflect high MET signaling and dependence. We hypothesized that assays reflecting MET signaling associated protein complexes could redefine tumors d…